41270-99-9

Upstream product

• 905589-81-3 (2,6-diphenylpyrimidin-4-yl)carbamic acid tert-butyl ester 
• 100-47-0 benzonitrile 
• 75-05-8 acetonitrile 
• 10132-07-7 4-amino-2,6-dichloropyrimidine 
• 98-80-6 phenylboronic acid 
• 905590-61-6 N-(5-benzyl-4-phenyl-1,3-thiazol-2-yl)-4-(3,4-diethoxyphenyl)-4-oxobutanamide 
• 75096-77-4 2,5-diphenyl-pyrrol-3-one oxime 
• 94-02-0 ethyl 3-oxo-3-phenylpropionate 
• 1670-14-0 benzamidine monohydrochloride 
• 15969-46-7 2,6-diphenyl-3H-pyrimidin-4-one 
• 29509-91-9 4-chloro-2,6-diphenyl-1,3-pyrimidine 
• 64-19-7 acetic acid 

Downstream Products

• 15969-46-7 2,6-diphenyl-3H-pyrimidin-4-one 

Relevant academic research and scientific papers

Compound, application thereof and organic electroluminescent device

The invention provides a compound, application thereof and an organic electroluminescent device. The compound has a structure shown as a formula (I). The compound is used as an electron transport material in an organic electroluminescent device; the organic electroluminescent device includes a first electrode, a second electrode, and an organic layer interposed between the first electrode and thesecond electrode, wherein the organic layer containing the compound. The compound provided by the invention has relatively high electron injection capability and electron migration capability, and when the compound is used for an organic electroluminescent device, the device can have relatively high light-emitting efficiency and relatively low working voltage.

Pyrimidine derivatives as potent and selective A3 adenosine receptor antagonists

Two regioisomeric series of diaryl 2- or 4-amidopyrimidines have been synthesized and their adenosine receptor affinities were determined in radioligand binding assays at the four human adenosine receptors (hARs). Some of the ligands prepared herein exhib

AMIDE COMPOUND

The present invention relate to a compound represented by the formula (I) or (II) wherein ring A is an optionally substituted ring (the ring should not be pyrrolidine, piperidine and piperazine), ring B is an optionally substituted aromatic ring, ring D is an optionally substituted ring, R1 and R2 are each independently a hydrogen atom or a substituent, R3 is a hydrogen atom or a C1-6 alkyl group, or R3 is bonded to ring A to form a non-aromatic ring, ring Aa is an optionally substituted aromatic hydrocarbon, Y is CH or N, Ra1 is an optionally substituted hydrocarbon group, and Ra2 and Ra3 are each independently a hydrogen atom or a substituent, or a salt thereof. The present invention provides a compound having a DGAT inhibitory activity, which is useful for the treatment or amelioration of diseases or pathologies caused by high expression or high activation of DGAT.

AMIDE COMPOUND

Disclosed is a compound represented by the formula (I) or (II) below, or a salt thereof. [In the formulae, ring A represents an optionally substituted ring (which is not a pyrrolidine, piperidine or piperazine); ring B represents an optionally substituted aromatic ring; ring D represents an optionally substituted ring; R1 and R2 independently represent a hydrogen atom or a substituent; R3 represents a hydrogen atom or a C1-6 alkyl group, or alternatively it combines with the ring A to form a non-aromatic ring; ring Aa represents an optionally substituted aromatic hydrocarbon; Y represents CH or N; Ra1 represents an optionally substituted hydrocarbon group; and Ra2 and Ra3 independently represent a hydrogen atom or a substituent.] The compound has a DGAT inhibitory effect and is useful for treatment or improvement of diseases or conditions caused by high expression or high activation of DGAT.

SUBSTITUTED PYRIMIDINES AS LIGANDS OF ADENOSINE RECEPTORS

The invention provides a compound of formula (I) wherein R and R' are selected from hydrogen, alkyl, alkenyl, alkynyl, or aryl; R'' and R''' are selected from hydrogen, acyl, thio-acyl, seleno-acyl, alkyl, alkenyl, alkynyl, or aryl; or a pharmaceutically

2,4,6-Trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists

Adenosine receptor antagonists usually possess a bi- or tricyclic heteroaromatic structure at their core with varying substitution patterns to achieve selectivity and/or greater affinity. Taking into account molecular modeling results from a series of pot